Moderna Seeks OK For Emergency Approval For COVID Vaccine, Now What?

The transcript discusses the progress of COVID-19 vaccines by Moderna and Pfizer, highlighting Moderna's 94% effectiveness in trials and the use of mRNA technology. Both vaccines are seeking emergency use authorization from the FDA, with hearings scheduled in December. Initial vaccine doses will be limited, with widespread availability expected by mid-next year. Public health measures remain crucial until vaccines are widely distributed. A CDC board will decide on vaccine prioritization.

What is the effectiveness rate of Moderna's COVID-19 vaccine in trials?

• 94%

• 70%

• 80%

• 60%

What technology does Moderna's vaccine use to trigger an immune response?

• Protein-based technology

• Viral vector technology

• DNA technology

• mRNA technology

When is the FDA review hearing for Pfizer's vaccine scheduled?

• December 20th

• December 15th

• December 10th

• December 1st

How many doses does Moderna expect to have ready for the US by the end of the year?

• 15 million

• 10 million

• 25 million

• 20 million

What is the expected timeline for the majority of Americans to receive the vaccine?

• First quarter of next year

• Second or third quarter of next year

• End of this year

• Fourth quarter of next year